Straits Times Index
3,314.05 +0.57 (+0.02%) S&P 500
5,309.96 +6.69 (+0.13%) Dow
39,828.06 -175.53 (-0.44%) Nasdaq
16,793.19 +107.22 (+0.64%) Bitcoin USD
68,768.35 +2,174.21 (+3.26%) CMC Crypto 200
1,427.00 +72.59 (+5.36%)
Trinity Biotech plc (TRIB)
| Previous close | 1.5800 |
| Open | 1.5799 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.5799 - 1.7200 |
| 52-week range | 1.4900 - 5.5000 |
| Volume | |
| Avg. volume | 20,922 |
| Market cap | 16.091M |
| Beta (5Y monthly) | 1.24 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 05 Jun 2015 |
| 1y target est | N/A |
- GlobeNewswire
Trinity Biotech Announces Strategic Collaboration with Medical Artificial Intelligence Company PulseAI
DUBLIN, Ireland, May 16, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced a strategic collaboration with medical artificial intelligence (“AI”) company PulseAI to enhance the Company’s recently acquired continuous glucose monitor (CGM) biosensor technology. Under this collaboration, Trinity Biotech will provide a pool of unique multi-p
- GlobeNewswire
Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance for 2024 TrinScreen HIV Sales
DUBLIN, Ireland, May 13, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced that it has received substantial additional orders for TrinScreen HIV, bringing total orders received to date for supply in 2024 to approximately $6 million. The Company has successfully scaled up production to meet the increased demand for its rapid HIV tests. A
- GlobeNewswire
Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development
DUBLIN, Ireland, May 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the appointment of Avinash Kale as Continuous Glucose Monitor (CGM) Programme Director. His appointment is a critical step forward in advancing the Company’s recently acquired CGM technology and in driving its innovation and development to bring an advanced CGM s
